Study: Some breast cancer patients with low genetic risk could skip chemotherapy
from University of California
Early stage breast cancer patients whose tumors carry genetic markers associated with a low risk of disease recurrence may not need to undergo chemotherapy, suggests a new study that employed a test devised by a University of California, San Francisco researcher. In the study, reported Aug. 24, in The New England Journal of Medicine, researchers profiled surgically removed tumors from nearly 6,700 patients using a genetic test known as MammaPrint, which predicts the risk of cancer recurrence by measuring the expression of a suite of 70 genes.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063